Diclofenac Potassium Powder for Oral Solution [Regulatives / Guidelines]

posted by Ahmed Al Habashi – UAE, 2014-08-16 07:08 (2841 d 13:28 ago) – Posting: # 13394
Views: 5,710

I would like to get your advice on the following important matter:

I have received a query from one of MOHs requesting us to justify the absence of BE study for our product “Diclofenac Potassium Powder for Oral Solution” due to presence of Mannitol (890 mg) in the formula.

They mentioned that as per the European BE guidelines, we must conduct a BE study for this product.

Hence, I request you to kindly share your experience related to this matter.

Your response will be highly appreciated.

Complete thread:

UA Flag
Activity
 Admin contact
22,110 posts in 4,630 threads, 1,567 registered users;
online 17 (0 registered, 17 guests [including 9 identified bots]).
Forum time: Friday 20:36 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5